Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

The alpha-1D Is the predominant alpha-1-adrenergic receptor subtype in human epicardial coronary arteries.

Jensen BC, Swigart PM, Laden ME, DeMarco T, Hoopes C, Simpson PC.

J Am Coll Cardiol. 2009 Sep 22;54(13):1137-45. doi: 10.1016/j.jacc.2009.05.056.

2.

Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific.

Jensen BC, Swigart PM, Simpson PC.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):409-12. doi: 10.1007/s00210-008-0368-6. Epub 2008 Nov 7.

3.

Carvedilol increases blood pressure response to phenylephrine infusion in heart failure subjects with systolic dysfunction: evidence of improved vascular alpha1-adrenoreceptor signal transduction.

Van Tassell BW, Rondina MT, Huggins F, Gilbert EM, Munger MA.

Am Heart J. 2008 Aug;156(2):315-21. doi: 10.1016/j.ahj.2008.04.004. Epub 2008 Jun 20.

4.

An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes.

Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC, O'Connell TD.

Circulation. 2007 Feb 13;115(6):763-72. Epub 2007 Feb 5.

5.

Effect of alpha1-adrenergic receptors in cardiac pathophysiology.

Shannon R, Chaudhry M.

Am Heart J. 2006 Nov;152(5):842-50. Review.

PMID:
17070143
6.

Transgenic alpha1A-adrenergic activation limits post-infarct ventricular remodeling and dysfunction and improves survival.

Du XJ, Gao XM, Kiriazis H, Moore XL, Ming Z, Su Y, Finch AM, Hannan RA, Dart AM, Graham RM.

Cardiovasc Res. 2006 Sep 1;71(4):735-43. Epub 2006 Jun 16.

7.

Alpha1-adrenergic receptors prevent a maladaptive cardiac response to pressure overload.

O'Connell TD, Swigart PM, Rodrigo MC, Ishizaka S, Joho S, Turnbull L, Tecott LH, Baker AJ, Foster E, Grossman W, Simpson PC.

J Clin Invest. 2006 Apr;116(4):1005-15.

9.

Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes.

Chaulet H, Lin F, Guo J, Owens WA, Michalicek J, Kesteven SH, Guan Z, Prall OW, Mearns BM, Feneley MP, Steinberg SF, Graham RM.

J Mol Cell Cardiol. 2006 Apr;40(4):540-52. Epub 2006 Mar 6.

PMID:
16516910
10.

alpha1A- but not alpha1B-adrenergic receptors precondition the ischemic heart by a staurosporine-sensitive, chelerythrine-insensitive mechanism.

Rorabaugh BR, Ross SA, Gaivin RJ, Papay RS, McCune DF, Simpson PC, Perez DM.

Cardiovasc Res. 2005 Feb 1;65(2):436-45.

11.

Genetic enhancement of ventricular contractility protects against pressure-overload-induced cardiac dysfunction.

Du XJ, Fang L, Gao XM, Kiriazis H, Feng X, Hotchkin E, Finch AM, Chaulet H, Graham RM.

J Mol Cell Cardiol. 2004 Nov;37(5):979-87.

PMID:
15522275
12.

Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.

Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P.

Circulation. 2004 Sep 14;110(11):1437-42. Epub 2004 Aug 30.

13.

Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).

Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, Wiltse C, Wright TJ; MOXCON Investigators.

Eur J Heart Fail. 2003 Oct;5(5):659-67.

14.

The alpha(1A/C)- and alpha(1B)-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse.

O'Connell TD, Ishizaka S, Nakamura A, Swigart PM, Rodrigo MC, Simpson GL, Cotecchia S, Rokosh DG, Grossman W, Foster E, Simpson PC.

J Clin Invest. 2003 Jun;111(11):1783-91.

15.

Differential cardiovascular regulatory activities of the alpha 1B- and alpha 1D-adrenoceptor subtypes.

Chalothorn D, McCune DF, Edelmann SE, Tobita K, Keller BB, Lasley RD, Perez DM, Tanoue A, Tsujimoto G, Post GR, Piascik MT.

J Pharmacol Exp Ther. 2003 Jun;305(3):1045-53. Epub 2003 Mar 20.

16.

Alpha 1-adrenergic receptor responses in alpha 1AB-AR knockout mouse hearts suggest the presence of alpha 1D-AR.

Turnbull L, McCloskey DT, O'Connell TD, Simpson PC, Baker AJ.

Am J Physiol Heart Circ Physiol. 2003 Apr;284(4):H1104-9. Epub 2002 Dec 5.

17.

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes.

Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F.

Genome Biol. 2002 Jun 18;3(7):RESEARCH0034. Epub 2002 Jun 18.

18.
19.

Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure.

Swedberg K, Bristow MR, Cohn JN, Dargie H, Straub M, Wiltse C, Wright TJ; Moxonidine Safety and Efficacy (MOXSE) Investigators.

Circulation. 2002 Apr 16;105(15):1797-803.

20.

Cardiovascular influences of alpha1b-adrenergic receptor defect in mice.

Vecchione C, Fratta L, Rizzoni D, Notte A, Poulet R, Porteri E, Frati G, Guelfi D, Trimarco V, Mulvany MJ, Agabiti-Rosei E, Trimarco B, Cotecchia S, Lembo G.

Circulation. 2002 Apr 9;105(14):1700-7.

Items per page

Supplemental Content

Write to the Help Desk